デフォルト表紙
市場調査レポート
商品コード
997513

重症筋無力症治療薬の世界市場

Myasthenia Gravis Drugs

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 125 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

重症筋無力症治療薬の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の重症筋無力症治療薬の市場規模は、分析期間(2020年~2027年)に8.7%のCAGRで成長する見通しで、2020年の13億米ドルから、2027年には23億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである薬物治療は、分析期間中に9.1%のCAGRで成長し、11億米ドルに達すると予測されています。

当レポートは、世界の重症筋無力症治療薬市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • CSL Limited
  • Curavac Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Flamel Technologies S.A.
  • Galenica Ltd.
  • GlaxoSmithKline PLC
  • Grifols SA
  • Lupin Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Shire PLC

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:38社
目次
Product Code: MCP13519

Abstract:

Global Myasthenia Gravis Drugs Market to Reach $2.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Myasthenia Gravis Drugs estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2027, growing at a CAGR of 8.7% over the analysis period 2020-2027. Drug Treatment, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Rapid Immunotherapies segment is readjusted to a revised 6.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $372.1 Million, While China is Forecast to Grow at 8.2% CAGR

The Myasthenia Gravis Drugs market in the U.S. is estimated at US$372.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$391.6 Million by the year 2027 trailing a CAGR of 8.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7% CAGR.

Thymectomy Segment to Record 10.7% CAGR

In the global Thymectomy segment, USA, Canada, Japan, China and Europe will drive the 10.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$195.8 Million in the year 2020 will reach a projected size of US$401.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$260.7 Million by the year 2027.

Select Competitors (Total 38 Featured) -

  • Alexion Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • CSL Limited
  • Curavac Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Flamel Technologies S.A.
  • Galenica Ltd.
  • GlaxoSmithKline PLC
  • Grifols SA
  • Lupin Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Shire PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Myasthenia Gravis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Myasthenia Gravis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Myasthenia Gravis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Drug Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Rapid Immunotherapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Rapid Immunotherapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Rapid Immunotherapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Thymectomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Thymectomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Thymectomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 13: USA Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: USA 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 16: Canada Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: Canada Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: Canada 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: Japan 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 22: China Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: China Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: China 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 25: Europe Current & Future Analysis for Myasthenia Gravis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Myasthenia Gravis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Myasthenia Gravis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 28: Europe Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 31: France Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: France Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: France 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 34: Germany Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Germany Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Germany 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 37: Italy Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Italy Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Italy 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 40: UK Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: UK Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: UK 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Rest of Europe Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Rest of Europe 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 46: Asia-Pacific Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Asia-Pacific Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Asia-Pacific 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 49: Rest of World Current & Future Analysis for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of World Historic Review for Myasthenia Gravis Drugs by Treatment - Drug Treatment, Rapid Immunotherapies and Thymectomy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of World 15-Year Perspective for Myasthenia Gravis Drugs by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Rapid Immunotherapies and Thymectomy for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 38